Clinical-stage Asia-Pacific biopharmaceutical company Antengene (SEHK: 6996) officially listed on the Main Board of The Stock Exchange of Hong Kong Limited on Nov. 20, 2020.
The listing of Antengene was the 11th public listing in Qiming’s portfolio in 2020. The firm started to invest in Antengene in August 2017 as the A round lead investor and followed on in its subsequent financing rounds.
Antengene is a clinical-stage Asia-Pacific biopharmaceutical company focused on innovative oncology medicines and R&D capabilities and differentiated strategic approach to developing novel oncology therapies.
Antengene has built a highly selective pipeline of 12 drug assets focused on oncology, including two late-stage clinical assets, four early-stage clinical assets and six pre-clinical stage assets. The company also has nine ongoing clinical trials and five clinical trials planned for initiation, and received nine IND approvals in multiple jurisdictions across the APAC regions.
FinSMEs
23/11/2020